Adverum biotechnologies initiates artemis phase 3 study evaluating ixo-vec for wet amd

Redwood city, calif., march 03, 2025 (globe newswire) -- adverum biotechnologies, inc. (nasdaq: advm), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announced the initiation of the artemis phase 3 study. this pivotal trial is designed to evaluate the efficacy and safety of ixo-vec (ixoberogene soroparvovec) as a one-time intravitreal (ivt) injection for patients with neovascular (wet) age-related macular degeneration (amd).
AMD Ratings Summary
AMD Quant Ranking